Shifting Paradigms in Drug Development

This chapter examines the evolving investment trends in the biotechnology sector with a focus on innovative drug development approaches that minimize traditional animal testing. It covers the licensing agreement between an American and a Chinese firm, the rise of DPP1 inhibitors, and the FDA and NIH's push towards alternative testing methods, including organoids and organ-on-chip models. The narrative highlights the ongoing debate and challenges associated with new approach methodologies (NAMs), balancing optimism for non-animal models against concerns about their reliability in research.